Hence, targeting these enzymes by PDE-5 inhibitors or sGC stimulators/activators could induce dilation of hepatic sinusoids, decrease intrahepatic resistance, increase portal venous blood flow, and consequently, lower portal pressure in cirrhotic portal hypertension. Here, SGCB is linked to portal hypertension.